Lisata Therapeutics wins new US patent for pancreatic cancer drug
Published: 14:10 08 Oct 2026 BST
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said.
The US Patent and Trademark Office issued the Method of Use patent titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors." It is set to expire in May 2041.
The patent covers administering certepetide, a proprietary cyclic peptide, alongside at least one anti-cancer agent or therapy. It applies to pancreatic cancer and other solid tumors, including metastatic, refractory and drug-resistant cancers, by treating, inhibiting and/or reducing tumor volume.
"This patent granted by USPTO secures important protection for the broad use of certepetide and provides added market exclusivity into November 2043, which is essential to support its continued development," said David Mazzo, Lisata's CEO.
Certepetide, formerly known as LSTA1, is an investigational internalizing RGD cyclic peptide designed to activate a novel uptake pathway. The pathway allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.
The company said certepetide also has been shown to modify the tumor microenvironment, making tumors more susceptible to immunotherapies.
Lisata and its collaborators have amassed significant non-clinical data showing enhanced delivery of a range of emerging therapies, including immunotherapies and RNA-based therapeutics.
To date, certepetide has demonstrated favorable safety, tolerability and clinical activity in completed and ongoing trials testing its ability to enhance standard-of-care chemotherapy for pancreatic cancer, the company said.